Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.60 |
| ▸ | MAPT | P10636 | 3/20 | 0.56 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.56 |
| ▸ | VCAM1 | P19320 | 2/20 | 0.54 |
| ▸ | PHGDH | O43175 | 1/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | RAF1 | P04049 | 1/20 | 0.50 |
| ▸ | HPGD | P15428 | 1/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.50 |
| ▸ | GFER | P55789 | 1/20 | 0.50 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.50 |
| ▸ | PDE7A | Q13946 | 1/20 | 0.50 |
| ▸ | HTT | P42858 | 1/20 | 0.50 |
| ▸ | APP | P05067 | 1/20 | 0.49 |
| ▸ | HCAR3 | P49019 | 2/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | NPC1 | O15118 | 1/20 | 0.48 |
| ▸ | RAB9A | P51151 | 1/20 | 0.48 |
| ▸ | CDC25B | P30305 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11150919 | 0.88 | HCAR3 (0.63) | KMT2AMAPTNPSR1VCAM1ALDH1A1 | |
| SCHEMBL10712446 | 0.86 | MAPT (0.64) | KMT2AMAPTNPSR1ALDH1A1LMNA | |
| SCHEMBL3620745 | 0.83 | KMT2A (0.65) | KMT2AMAPTNPSR1ALDH1A1HTT | |
| SCHEMBL29793669 | 0.83 | KMT2A (0.68) | KMT2AMAPTNPSR1ALDH1A1HTT | |
| SCHEMBL2643864 | 0.83 | KMT2A (0.68) | KMT2AMAPTNPSR1ALDH1A1HTT | |
| SCHEMBL3613079 | 0.81 | HCAR3 (0.72) | KMT2AMAPTNPSR1HCAR3MEN1 | |
| SCHEMBL10108037 | 0.81 | KMT2A (0.54) | KMT2AMAPTNPSR1PHGDHPDE7A | |
| SCHEMBL11707399 | 0.81 | KMT2A (0.62) | KMT2AMAPTNPSR1ALDH1A1HTT | |
| SCHEMBL11660364 | 0.80 | MAPT (0.54) | KMT2AMAPTNPSR1ALDH1A1LMNA | |
| SCHEMBL10102442 | 0.80 | MAPT (0.54) | KMT2AMAPTNPSR1PHGDHALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9115084-B2 | 6-alkenyl and 6-phenylalkyl substituted 2-quinolinones and 2-quinoxalinones as poly(ADP-ribose) polymerase inhibitors | JANSSEN PHARMACEUTICA, NV (BE) | 2015-08-25 | — | — | US | disclosed |
| EP-1709011-B1 | 7-PHENYLALKYL SUBSTITUTED 2-QUINOLINONES AND 2 QUINOXALINONES AS POLY(ADP-RIBOSE) POLYMERASE INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2015-07-29 | — | — | EP | disclosed |
| US-20130237528-A1 | 6-ALKENYL AND 6-PHENYLALKYL SUBSTITUTED 2-QUINOLINONES AND 2-QUINOXALINONES AS POLY(ADP-RIBOSE) POLYMERASE INHIBITORS | JANSSEN PHARMACEUTICA, NV (BE) | 2013-09-12 | — | — | US | disclosed |
| US-8524714-B2 | 7-phenylalkyl substituted 2-quinolinones and 2-quinoxalinones as poly(ADP-ribose) polymerase inhibitors | JANSSEN PHARMACEUTICA, NV (BE) | 2013-09-03 | — | — | US | disclosed |
| US-8450486-B2 | 6-alkenyl and 6-phenylalkyl substituted 2-quinolinones and 2-quinoxalinones as poly(ADP-ribose) polymerase inhibitors | JANSSEN PHARMACEUTICA, NV (BE) | 2013-05-28 | — | — | US | disclosed |
| US-20120046274-A1 | 6-ALKENYL AND 6-PHENYLALKYL SUBSTITUTED 2-QUINOLINONES AND 2-QUINOXALINONES AS POLY(ADP-RIBOSE) POLYMERASE INHIBITORS | MABIRE DOMINIQUE JEAN-PIERRE (FR) | 2012-02-23 | — | — | US | disclosed |
| US-8071612-B2 | 6-alkenyl and 6-phenylalkyl substituted 2-quinolinones and 2-quinoxalinones as poly(ADP-ribose) polymerase inhibitors | JANSSEN PHARMACEUTICA, NV (BE) | 2011-12-06 | — | — | US | disclosed |
| US-20110230492-A1 | 7-PHENYLALKYL SUBSTITUTED 2-QUINOLINONES AND 2-QUINOXALINONES AS POLY(ADP-RIBOSE) POLYMERASE INHIBITORS | MABIRE DOMINIQUE JEAN-PIERRE | 2011-09-22 | — | — | US | disclosed |
| US-20110124673-A1 | 6-ALKENYL AND 6-PHENYLALKYL SUBSTITUTED 2-QUINOLINONES AND 2-QUINOXALINONES AS POLY(ADP-RIBOSE) POLYMERASE INHIBITORS | MABIRE DOMINIQUE JEAN-PIERRE | 2011-05-26 | — | — | US | disclosed |
| US-7928104-B2 | Enhances sensitivity to radiotherapy and chemotherapy; synergistic; hydrolysis of a 2-methoxyquinoline or 2-methoxyquinoxaline; cyclization of a N-phenyl phenylacrylamide; or condensation of an o-benzenediamine with a keto-ester; preferred oxalate salt; side effect reduction | JANSSEN PHARMACEUTICA N.V. (BE) | 2011-04-19 | — | — | US | disclosed |
| US-7855207-B2 | 6-alkenyl and 6-phenylalkyl substituted 2-quinolinones and 2-quinoxalinones as poly(adpribose) polymerase inhibitors | JANSSEN PHARMACEUTICA, NV (BE) | 2010-12-21 | — | — | US | disclosed |
| US-20080249099-A1 | Enhances sensitivity to radiotherapy and chemotherapy; synergistic; hydrolysis of a 2-methoxyquinoline or 2-methoxyquinoxaline; cyclization of a N-phenyl phenylacrylamide; or condensation of an o-benzenediamine with a keto-ester; preferred oxalate salt; side effect reduction | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-10-09 | — | — | US | disclosed |
| US-20070072842-A1 | 6-Alkenyl and 6-phenylalkyl substituted 2-quinolinones and 2-quinoxalinones as poly(adpribose) polymerase inhibitors | JANSSEN-CILAG (FR) | 2007-03-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070072842-A1 | 6-Alkenyl and 6-phenylalkyl substituted 2-quinolinones and 2-quinoxalinones as poly(adpribose) polymerase inhibitors | PARP1, PARP6, PARP2 | KMT2A 744/4885MAPT 2275/4885NPSR1 2832/4885 |
| US-20080249099-A1 | Enhances sensitivity to radiotherapy and chemotherapy; synergistic; hydrolysis of a 2-methoxyquinoline or 2-methoxyquinoxaline; cyclization of a N-phenyl phenylacrylamide; or condensation of an o-benzenediamine with a keto-ester; preferred oxalate salt; side effect reduction | PARP1, PARP2, PARP3 | KMT2A 491/4885MAPT 2479/4885NPSR1 2503/4885 |
| US-20110124673-A1 | 6-ALKENYL AND 6-PHENYLALKYL SUBSTITUTED 2-QUINOLINONES AND 2-QUINOXALINONES AS POLY(ADP-RIBOSE) POLYMERASE INHIBITORS | PARP1, PARP2, PARP6 | KMT2A 760/4885MAPT 2886/4885NPSR1 3556/4885 |
| US-20110230492-A1 | 7-PHENYLALKYL SUBSTITUTED 2-QUINOLINONES AND 2-QUINOXALINONES AS POLY(ADP-RIBOSE) POLYMERASE INHIBITORS | PARP1, PARP2, PARP3 | KMT2A 797/4885MAPT 3352/4885NPSR1 2958/4885 |
| US-20130237528-A1 | 6-ALKENYL AND 6-PHENYLALKYL SUBSTITUTED 2-QUINOLINONES AND 2-QUINOXALINONES AS POLY(ADP-RIBOSE) POLYMERASE INHIBITORS | PARP1, PARP2, PARP6 | KMT2A 760/4885MAPT 2886/4885NPSR1 3556/4885 |
| US-20120046274-A1 | 6-ALKENYL AND 6-PHENYLALKYL SUBSTITUTED 2-QUINOLINONES AND 2-QUINOXALINONES AS POLY(ADP-RIBOSE) POLYMERASE INHIBITORS | PARP1, PARP2, PARP6 | KMT2A 760/4885MAPT 2886/4885NPSR1 3556/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.